title: Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
abstract: Plasma endothelin-1 (ET-1) is elevated in patients with sickle cell disease (SCD). Hydroxyurea (HU) is the only drug with demonstrated clinical efficacy in SCD. Here we show that treatment with HU results in a decreased concentration of circulating ET-1 which is not correlated with the HU-induced increase in HbF level. Blunting of the ET-1 vasoconstrictive stimulus could contribute to the beneficial effects of HU.
authors.forename: Claudine
authors.initials: C
authors.lastname: Lapouméroulie
authors.forename: Malika
authors.initials: M
authors.lastname: Benkerrou
authors.forename: Marie Hélène
authors.initials: MH
authors.lastname: Odièvre
authors.forename: Rolande
authors.initials: R
authors.lastname: Ducrocq
authors.forename: Manuel
authors.initials: M
authors.lastname: Brun
authors.forename: Jacques
authors.initials: J
authors.lastname: Elion
mesh_terms: D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D016022:Case-Control Studies; D002648:Child; D019332:Endothelin-1 / Q000097:blood*; D005319:Fetal Hemoglobin / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*
chemical_list: D019332:Endothelin-1; D005319:Fetal Hemoglobin; D006918:Hydroxyurea